恩格列净降低心力衰竭患者高钾血症发生率:EMPEROR-Pooled分析
EMPEROR-Pooled分析纳入9583例心力衰竭患者,评估恩格列净对高钾血症和低钾血症的影响。结果显示恩格列净较安慰剂降低研究者报告的高钾血症或启动钾结合剂的复合终点(6.5% vs 7.7%,HR 0.82,95%CI 0.71-0.95,P=0.01),且未显著增加低钾血症。
要点
- 恩格列净降低高钾血症或启动钾结合剂的复合终点(HR 0.82)。
- 恩格列净降低血清钾>5.5 mmol/L和>6.0 mmol/L的高钾血症发生率。
- 恩格列净未显著增加低钾血症发生率。
核心结论
- 恩格列净降低心力衰竭患者高钾血症发生率,且未显著增加低钾血症。
研究设计与样本
- EMPEROR-Pooled分析合并EMPEROR-Reduced和EMPEROR-Preserved,纳入9583例基線有血清钾水平的心力衰竭患者。
主要发现
- 恩格列净组研究者报告高钾血症或启动钾结合剂的复合终点发生率为6.5%,安慰剂组为7.7%(HR 0.82,95%CI 0.71-0.95,P=0.01)。
- 血清钾>5.5 mmol/L的高钾血症发生率恩格列净组8.6%,安慰剂组9.9%(HR 0.85,95%CI 0.74-0.97,P=0.017)。
- 血清钾>6.0 mmol/L的高钾血症发生率恩格列净组1.9%,安慰剂组2.9%(HR 0.62,95%CI 0.48-0.81,P<0.001)。
- 低钾血症(研究者报告或血清钾<3.0 mmol/L)发生率在恩格列净组未显著增加。
临床怎么用
- 恩格列净可用于降低心力衰竭患者高钾血症风险,有助于维持神经激素拮抗剂治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may have important clinical implications. This analysis evaluates the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF. METHODS AND RESULTS: EMPEROR-Pooled (i.e. EMPEROR-Reduced and EMPEROR-Preserved combined) included 9583 patients with available serum potassium levels at baseline (98.6% of the total EMPEROR-Pooled population, n = 9718). Hyperkalaemia was identified by investigators' reports of adverse events, and by a laboratory serum potassium value above 5.5 mmol/L and 6.0 mmol/L. The main outcome was a composite of investigator-reported hyperkalaemia or initiation of potassium binders. Patients with high potassium at baseline were more frequently diagnosed with diabetes and ischaemic HF aetiology and had lower left ventricular ejection fraction and estimated glomerular filtration rate but were more frequently treated with sacubitril/valsartan or mineralocorticoid receptor antagonists. Empagliflozin (compared with placebo) reduced the composite of investigator-reported hyperkalaemia or initiation of potassium binders [6.5% vs. 7.7%, hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.95, P = 0.01]. Empagliflozin reduced hyperkalaemia rates regardless of the definition used (serum potassium >5.5 mmol/l: 8.6% vs. 9.9%, HR 0.85, 95% CI 0.74-0.97, P = 0.017; serum potassium >6.0 mmol/l: 1.9% vs. 2.9%, HR 0.62, 95% CI 0.48-0.81, P < 0.001). The incidence of hypokalaemia (investigator-reported or serum potassium <3.0 mmol/l) was not significantly increased with empagliflozin. CONCLUSIONS: Empagliflozin reduced the incidence of hyperkalaemia without significant increase in hypokalaemia.
引用
- Ferreira, Zannad, Butler, et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J. 2022. PMID: 35687107. doi:10.1093/eurheartj/ehac306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。